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Abstract
Endothelial Progenitor Cells (EPC) were first described in 1997 and have since been the subject of numerous inves-
tigative studies exploring the potential of these cells in the process of cardiovascular damage and repair. Whilst
their exact definition and mechanism of action remains unclear, they are directly influenced by different cardiovas-
cular risk factors and have a definite role to play in defining cardiovascular risk. Furthermore, EPCs may have impor-
tant therapeutic implications and further understanding of their pathophysiology has enabled us to explore new
possibilities in the management of cardiovascular disease. This review article aims to provide an overview of the
vast literature on EPCs in relation to clinical cardiology.
Introduction
Maintenance of endothelial integrity and functioning is
vital to the preservation of a healthy vasculature [1].
Thus, the impairment as well as insufficient recovery
potential of the endothelial cell monolayer is believed to
be a critical factor during the initiaton and progression
of atherosclerosis [2]. Indeed, endothelial damage/dys-
function has been proved to be involved in the patho-
genesis of atherothrombotic vascular disease, with
important prognostic and therapeutic implications.
Although the possibility that adult endothelial precur-
sors may exist was suggested more than four decades
ago, Asahara et al. first reported isolation of putative
adult endothelial precursors which we now recognize as
endothelial progenitor cells (EPCs), only in 1997 [3,4].
Endothelial progenitors were able to differentiate into
mature endothelial cells and promote repair of damaged
endothelium [5-8]. Progressively increasing number of
studies has been devoted to these enigmatic cells in the
recent years and their close association with multiple
markers of cardiovascular health is now well-recognised.
Apart from a diagnostic and prognostic role, EPCs
may be attractive target for treatment and, at the same
time, be used themselves in an attempt to stimulate
angiogenesis, vasculogenesis and cardiac performance.
As an example, CD34 antibody coated stents designed
to attract EPCs to the healing endothelium are under
intensive clinical trial investigation. However, the precise
role of EPCs in vascular pathology still needs to be
further clarified as results of some currently available
studies in the literature are controversial.
This article aims to provide an overview of the vast
literature on EPCs in relation to clinical cardiology.
EPCs ageing and physical activity
Physiological factors and conventional risk factors for
atherosclerosis are associated with variations of the
number and activity of endothelial progenitors and may
be the bridge linking EPCs to common cardiovascular
d i s o r d e r ss u c ha sc o r o n a r ya rtery disease (CAD), myo-
cardial infarction and heart failure.
EPC characteristics are closely associated with the pre-
sence of various cardiovascular risk factors (Table 1).
EPC numbers or function - or both - may be affected.
For example, smoking contributes towards reducing the
number of circulating EPCs, whilst hypertension reduces
migratory capacity [9]. Serum LDL cholesterol levels, a
positive family history of CAD, and age have all been
shown to influence the number and migration of circu-
lating CD34
+ cells and EPCs [9].
There is an age-related quantitative decline in bone
marrow cells expressing endothelial progenitor markers
[3]. Jie et al analysed the number of circulating CD34
+/KDR
+ EPCs in healthy subjects aged from 1 to 81
years old, and an inverse relationship with age was
* Correspondence: g.y.h.lip@bham.ac.uk
† Contributed equally
1Haemostasis, Thrombosis and Vascular Biology Unit, University of
Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
UK
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6 JOURNAL OF
ANGIOGENESIS RESEARCH
© 2010 Siddique et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.observed [10]. The progressive reduction in different
progenitor cell populations with age was also confirmed
by Shaffer et al, both in healthy donors and in patients
with peripheral arterial disease [11]. Impairment of the
functional activity of endothelial progenitors also paral-
lels downregulation of their numbers [12]. This decline
in EPC clonogenic capacity appears to occur at an ear-
lier age, followed by a decline in migratory activity.
Admittedly, some controversy still exists on the rela-
tionship of age to EPC levels. For example, Pelliccia et
al failed to find any difference in absolute numbers of
CD34+, CD133
+, CD105
+,a n dC D 1 4
+ cells in older
patients with CAD indicating a strong impact of factors
other than age for the presence in atherosclerosis and
re-emphasising the necessity of having a precise defini-
tion of EPC populations studied [13]. The decrease in
EPC recruitment in the elderly may be associated with
downregulation of tissue hypoxia-inducible factor 1 or
insufficient local expression of VEGF, one of the key
attractors of EPCs [14]. Furthermore, over an indivi-
dual’s lifetime, long-lived cells such as bone marrow
endothelial precursors incur repeated exposures to oxi-
dative stress; initially, EPCs may compensate by increas-
ing their antioxidant responses to prevent oxidant
injury. Over time, oxidant damage is likely to accumu-
late, thus diminishing the functional properties of EPCs.
Physical activity effectively promotes EPC health in
terms of quantity, functional capacity and the prevention
of apoptosis [15]. This effect is rapid and sustained, at
least for 4 weeks [15]. Importantly, physical activity
positively affects both bone marrow and peripheral EPC
levels [15]. Furthermore, studies in animals have shown
that physical activity enhances replacement of the dys-
functional endothelium by bone marrow-derived cells
[16].
A rapid increase of EPC numbers following physical
exertion may be attributable to acute mobilisation of
the bone marrow EPC pool or a shear stress-induced
release into circulation of vessel-wall resident EPCs
[17,18]. Again, NO-dependent mechanisms may by
involved, given that physical exercise increases NO
bioavailability [19]. The effect of physical activity on
EPCs may be reduced by inhibition of endogenous NO
synthase [20].
EPCs and cardiovascular risk factors
Hypercholesterolemia negatively affects both EPC num-
ber and function. Indeed, EPC count has an inverse rela-
tionship with total cholesterol and LDL-cholesterol
levels [9]. Enhanced oxidative stress associated with dys-
lipidaemia may at least be partly involved in the dysre-
gulation of EPC mobilisation, maturation and survival.
Of note, circulating EPCs are very sensitive to oxidized
LDL, resulting in premature apoptosis [21,22].
Enhanced endothelial dysfunction and damage may
result in higher tissue demand for EPCs and their
increased turnover. Hypercholesterolaemia may also
directly affect the bone marrow, resulting in depletion
or exhaustion of the bone marrow pool of endothelial
progenitors, with a consequent limited supply of EPCs
released into circulation [23]. Also, LDL cholesterol
levels have an inverse relation with EPC migratory capa-
city [23]. Elevated LDL cholesterol and oxidized LDL
levels impair EPC migration, via a VEGF-mediated path-
way, and oxidized LDL blocks VEGF-induced EPC
migration through the inhibition of NO production
[24,25].
Reduced levels of EPCs have been described in both
type 1 and type 2 diabetes mellitus [26]. EPC recruit-
ment for re-endothelialization after vascular injury is
impaired in patients with diabetes, and as a consequence
of such EPC dysfunction, the vascular regenerative
potential of this disease group may be reduced - thus,
contributing to the development of vascular complica-
tions [27]. Indeed, decreased numbers and functional
activity of early EPCs are significantly associated with
the pathogenesis of vascular complications in either type
1 or type 2 diabetes [26,27].
Table 1 Effects of cardiovascular risk factors on EPC number and function
Cardiovascular risk factors Effect on EPC number and function EPC category References
Hypercholesterolemia Reduced EPC number, impaired EPC migratory capacity Circulating EPCs (CD133, 34, 45)
CFU-ECs
[9,23]
Diabetes Mellitus Reduced EPC number, impaired EPC migratory capacity Circulating EPCs (CD31, 34, KDR)
CFU-ECs
[26,27,29,30]
Hypertension Inverse relationship of EPC number with systolic blood pressure Circulating EPCs (CD133, 34, KDR) [9,34]
Smoking Affects EPC number in a dose-dependent manner Circulating EPCs (CD133, 34, KDR)
CFU-ECs
[35,36]
Ageing Reduced migration and proliferation Circulating EPCs (CD133, 34, 45)
CFU-ECs
[10-14,113]
Exercise Increased EPC number and function Circulating EPCs (CD133, 34, 45)
CFU-ECs
[15,17-20]
EPC - endothelial progenitor cells
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by EPCs with a corresponding decline in nitric oxide
(NO) bioavailability [31]. The effects of high glucose
could be ameliorated by co-incubation of EPCs with the
NO donor sodium nitroprusside or p38 mitogen-acti-
vated protein kinase inhibitor, and deteriorated by
eNOS inhibitor [28]. In contrast, antioxidants including
vitamin C, N-acetylcysteine and polyethylene glycol-con-
jugated superoxide dismutase, and polyethylene glycol-
catalase have no significant effects on EPCs [28]. This
suggests that the inhibitory effects of high glucose on
EPC could be reversed by NO donors, but not by var-
ious antioxidants.
Systolic blood pressure has a negative correlation with
the number of circulating EPCs, but the clonogenic
potential (number of CFU-ECs) is not impaired by arter-
ial hypertension [9]. Angiotensin II accelerates the onset
of EPC senescence, leading to impaired proliferation of
EPCs; this seems to be inhibited by treatment with the
angiotensin II type 1 receptor blocker, valsartan [29].
Ramipril also improves the proliferation and migration
of EPCs, as well as in vitro vasculogenesis in patients
with CAD [30].
These observations were confirmed in the Endothelial
Progenitor Cells in Coronary Artery Disease (EPCAD)
study, demonstrating that angiotensin-converting enzyme
inhibitor treatment was associated with increased num-
bers and improved clonogenic potential of circulating
EPCs, when compared with patients who were not taking
angiotensin-converting enzyme inhibitors [31].
Whilst smoking leads to a reduction in EPC counts,
nicotine itself may have a positive effect on EPC num-
bers and functional activity at low concentrations
[32,33]. This is supported by the finding that the use of
nicotine patches slightly increases the magnitude of the
rise in EPC levels after smoking cessation [32]. However,
higher nicotine levels will have cytotoxic effects on
EPCs, indicating complex effects of nicotine on EPCs
[33]. Indeed, the number of EPCs is reduced in chronic
smokers, whilst cessation of smoking leads to rapid
restoration of EPC levels [32]. In contrast, smoking ces-
sation leads to rapid recovery of the circulating EPC
population, especially amongst light smokers [32].
Recent studies have established a clear link between
levels of circulating EPCs and the cumulative cardiovas-
cular risk profile [8]. For example, Hill et al[8] hypothe-
sized that EPCs derived from the bone marrow have a
role in ongoing endothelial repair and thus, the deple-
tion of these cells contributes to cardiovascular disease
progression. Also, the number of CFU-EC colonies from
peripheral blood correlates closely with endothelial func-
tion. Thus, EPC levels could be used as a ‘biological
marker’ (or biomarker) for vascular function and the
relationship to cumulative cardiovascular risk.
Although mechanisms linking cardiovascular risk fac-
tors and the impairment of EPC mobilization and func-
tion are not sufficiently well understood, the number of
studies strongly indicates that chronic inflammation and
oxidative stress may play a critical role, despite substan-
tial resistance of endothelial progenitors to oxidative
burden [34-36].
EPCs and cardiovascular pathology
Atherosclerotic disease progression
Reduced levels of circulating EPCs have been shown to
be independent predictors of atherosclerotic disease pro-
gression [37]. Indeed, endothelial integrity is a fine bal-
ance between endothelial damage and repair [37]. Since
atherosclerotic risk factors are associated with reduced
numbers and function of circulating EPCs, it is possible
that progression of atherosclerosis is ‘driven’ by an
impairment of EPC repairing capacity [9].
In addition, disease processes that ‘damage’ the
endothelium per se lead to endothelial cell detachment,
resulting in increased levels of circulating endothelial
cells (CECs) in the blood [38]. CECs are thought to be
mature cells that have detached from the intimal mono-
layer in response to endothelial injury and are a differ-
ent cell population to EPCs [38]. There is increasing
evidence to support a relation between endothelial
damage/dysfunction and CECs [39,40]. An inverse rela-
tionship has been found between EPCs and CECs, as
elevated numbers of CECs have been seen in patients
with CAD whereas a reduction in the number of circu-
lating EPCs has been associated with CAD [39-41].
Stable coronary artery disease
An inverse relationship has been found between circu-
lating EPCs and CAD severity, independently of tradi-
tional risk factors [42] (Table 2). Indeed, patients with
multivessel CAD, had significantly lower EPC counts as
compared to those without - for every increase in 10
clusters of CFU-ECs, a patient’s likelihood for multives-
sel CAD declined by 20% [42]. In contrast, Guven et al
[43] showed that the number of EPCs was increased
among patients with significant CAD especially in those
requiring coronary intervention, and EPC numbers cor-
related with the maximum angiographic stenosis sever-
ity. The discrepancy between these two studies might be
attributable to the degree of ischemia experienced by
patients included as more severe ischemia in patients
required intervention could be responcible for EPC
mobilization.
Measurement of EPCs is of predictive value for cardi-
ovascular outcomes in stable CAD patients. For exam-
ple, Werner et al measured EPCs positive for the CD34
and KDR in 519 patients with CAD confirmed on cor-
onary angiography, and evaluated the association
between baseline levels of EPCs and major adverse
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for age, sex, vascular risk factors and other relevant vari-
ables, increased levels of EPCs were associated with a
reduced risk of death from cardiovascular causes, a first
major cardiovascular event, revascularization and hospi-
talization. This association was independent of severity
of CAD, cardiovascular risk factors and drug therapies
known to influence cardiovascular outcomes.
Of interest, EPC number and function is closely asso-
ciated with coronary endothelial function. In 90 patients
with CAD coronary endothelial function was assessed
using an intracoronary acetylcholine with quantitative
coronary angiography [44]. The number of circulating
CD133
+ or CD34
+/KDR
+ EPCs and EPC function esti-
mated by proliferation of CFU-ECs inversely correspon-
dent with the degree of endothelial function impairment
[44]. Multivariate analysis showed that the number of
EPCs predicted severe endothelial dysfunction indepen-
dently of classical cardiovascular risk factors.
Acute coronary syndromes
Acute coronary syndromes (ACS) are associated with
increased levels of inflammatory and haematopoietic
cytokines, which in turn can mobilise progenitor cells
from the bone marrow [45-47]. Of the many studies in
t h i sp a t i e n tg r o u p ,S h i n t a n ie ta lw e r et h ef i r s tt o
describe a rapid and significant increase in the CD34
+
EPC numbers, which reached a maximum at 7 days
after the onset of ischaemia in acute myocardial infarc-
tion (AMI) [48]. Similarly, Massa et al described sponta-
neous mobilisation and a 5.8-fold increase of CD34
+
progenitor cells, which peaked about 3 hours after the
onset of symptoms, significantly decreased after 7 days,
and reached levels comparable with those of healthy
subjects within 2 months [46]. Other cell subpopula-
tions, such as CD34
+/CD117
+,C D 3 4
+/CXCR4
+,C D 3 4
+/CD38
+ and CD34
+/CD45
+ broadly follow the same
pattern as that of EPCs [45,46]. Sufficient EPC numbers,
as well as the capacity to differentiate into mature
endothelial cells are considered to be essential for myo-
cardial functional recovery and infarct size reduction
after AMI [49].
Of note, the type of revascularization (ie, thrombolytic
therapy or primary angioplasty) does not seem to affect
EPC mobilization [50]. However, ischemia per se may
be a primary factor for EPC mobilization, given a signifi-
cant rise of EPC numbers in patients with unstable
angina [50]. An inflammatory state, as shown by high
C-reactive protein levels, is also involved in the modula-
tion of adhesive properties of EPCs in ACS [51].
Congestive heart failure
Biphasic changes of the number of CD34+ cells and
EPCs have been observed in patients with heart failure.
EPCs are significantly up-regulated in mild heart failure
(NYHA class I-II) but their mobilization is severely
depressed in patients with advanced heart failure
(NYHA III-IV) irrespectively of the origin of the disease
[52,53]. Depletion in EPCs has been correlated with
high levels of TNF-a indicating that endothelial precur-
sors arem additional ‘victim’ of excessive inflammation
seen in heart failure [52]. These data are in accordance
with observations in animal model that statin-induced
prevention of left ventricular dysfunction was strongly
associated the ability of statins to mobilize EPCs [54].
The proportion of CD34+ cells in hospitalised patients
with congestive heart failure increases with the improve-
ment of clinical status and is correlated with BNP levels.
Of note, Michowitz et al have recently demonstrated
that the CFU-EC numbers, together with age and pre-
sence of diabetes were independent predictor of all-
cause mortality in 107 patients with congestive heart
failure [55].
Coronary artery in-stent restenosis and cardiac surgery
Restenosis after coronary artery stenting remains a sig-
nificant problem in the practice of interventional cardi-
ology [56]. Prevention of restenosis may be promoted by
endothelial regeneration through the administration of
growth factors, endothelial cell seeding, vessel recon-
struction with autologous endothelial cell/fibrin matrix,
and the use of stents designed to attract and capture
EPCs [56].
Traditionally, the regeneration of injured endothelium
has been believed to be due to the migration and
Table 2 Effect of cardiovascular diseases on EPC number and function
Cardiovascular disorders Effect on EPC number and function EPC category References
Acute coronary syndrome Increased EPC number and function Circulating EPC (CD34, 45,133)
CFU-ECs
[45-48]
Atherosclerotic disease progression Reduced EPC number Circulating EPC (CD14)
CFU-ECs
[37]
Severity of coronary artery disease Reduced EPC number/Increased EPC number Circulating EPC (CD34, 133, KDR)
CFU-ECs
[34,42,43]
Heart failure Increased EPC number at early mild heart failure, decreased
EPC number in severe heart failure
CFU-ECs [52,53]
EPC - endothelial progenitor cells
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hypothesis has been challenged by animal studies, which
reveal that transfusion of EPCs led to reduced intimal
thickening of the injured arterial wall, as a result of
accelerated reendothelialization [57]. Stents coated with
an integrin-binding cyclic Arg-Gly-Asp peptide appear
to limit coronary neointima formation and accelerates
endothelialization by attracting EPCs, at least in an ani-
mal model [58].
What are the implications for therapy? The MAGIC
cell trial demonstrated that G-CSF therapy with intra-
coronary infusion of peripheral blood stem cells
improved cardiac function, and promoted angiogenesis
in patients with acute myocardial infarction(AMI) [59].
At the same time, the concern over aggravation of reste-
nosis was raised. However, the MAGIC Cell-3-DES trial
showed that G-CSF - based stem cell therapy was both
feasible and safe with DES implantation, eliminating the
risk of restenosis [60].
Nonetheless, G-CSF administration itself has been
shown to be associated with enhanced neointimal hyper-
plasia, possibly by the stimulation of excessive prolifera-
tion and the migration of smooth muscle cells, thus
promoting re-stenosis of stented arteries [61]. Moreover,
the possibility remains that EPCs may be independently
responsible for stent restenosis, as a strong correlation
has been shown between circulating CD34
+ cells and
late luminal loss following coronary angiography [62]. In
a multivariate regression model, a change in CD34+
cells independently predicts late lumen loss [63]. How-
ever, CD34 cells may be the ones that aggravated in
stent restenosis per se. CD34 cells are not authentic
EPCs but myeloid stem cells/progenitors that may dif-
ferentiate into smooth muscle cells depending on the
situation or in the presence of platelet derived growth
factor [63].
The role of EPCs in process of post-arterial injury
recovery/impairment is pretty complex. The ability of
EPCs to home to arterial neointima was initially shown
in a experimental minipig model [64]. Inoue et al sub-
ssequently confirmed that an increase in EPC numbers
following bare-metal stent implantation in patients with
CAD and the extent of EPC elevation correlated with
the risk of stent restenosis [65]. In contrast, DESs (eg,
sirolimus-eluting stents) are capable of preventing pro-
cedure-related EPC mobilization [65].
Rapamycin has been also shown to inhibit prolifera-
tion, migration, and differentiation of human EPCs in
vitro, suggesting that the targeting of EPCs may be an
additional mechanism of their successful prevention of
re-stenosis by the employment of DESs [66]. Indeed, a
reduction of EPC numbers may be one mechanism
through which drug-eluting stents actually inhibit reste-
nosis. Of note, cell-cycle inhibitors (sirolimus and
paclitaxel) reduce neointimal formation by impeding
smooth muscle cells proliferation and migration, as well
as cause impairment of the normal process of healing of
the injured arterial wall, leading to delayed re-endothe-
lialization [67].
Are EPCs really a negative factor in interventional
procedures? In contrast to the data where increased
numbers of EPCs lead to excessive neointima hyperpla-
sia, Matsuo et al have demonstrated that circulating
EPCs in patients with in-stent restenosis grow less colo-
nies of CFU-ECs and these cells have signs of increased
senescence compared to patients with successful arterial
healing [68]. Increased number of senescent EPCs were
an independent predictor of stent restenosis, but these
data also suggest that functional characteristics of EPCs
- rather than numbers per se - may be critical for effi-
cient re-endothelisation. However, one has to keep in
mind that circulating CD34+ cells are not exclusively
made up of endothelial precursors but also of hemato-
poietic stem cells and attraction of CD34+ cells may
also involve homing of certain populations of inflamma-
tory leukocytes to sites of vascular damage.
The numbers of circulating EPCs may be significantly
affected by cardiac surgery, including coronary artery
bypass grafting and valve surgery. For example, Smadja
et al demonstrated selective mobilisation of endothelial
progenitors after different cardiac operations [69], prob-
ably in response to tissue damage and application of
cardiovascular bypass. Indeed, the mobilization of EPCs
from the bone marrow may be promptly stimulated by
cardiopulmonary bypass but the extent of such mobilisa-
tion is significantly affected by pre-existing risk factors
and the European System for Cardiac Operative Risk
Evaluation (EuroSCORE) score. Further research is
needed to establish the dynamics of EPC during or fol-
lowing cardiac surgery, and how this affects prognosis
[70].
Therapeutic modification of EPCs
Statins
Statin therapy is associated with an increase in the num-
ber of circulating EPCs in patients with CAD [20]
(Table 3). The increase in EPCs and improvement of
their migratory capacity was significant as early as at 1
week after the initiation of treatment with atorvastatin,
w i t ha3 - f o l di n c r e a s ea t3t o4w e e k so ft h e r a p y[ 2 0 ] .
The mobilization of circulating EPCs, along with their
enhanced functional activity may contribute to the bene-
ficial effects of statins in patients with CAD [20]. The
migration and incorporation of EPCs to the sites of re-
endothelialization was found significantly increased after
statin administration [20,71].
While short-term treatment with statins has been
seen to increase both EPC number and function, more
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contrary. Indeed, there is a biphasic effect of statins on
EPC counts. In one study of 144 patients with angiogra-
phically documented CAD, the administration of statins
for more then 4 weeks resulted in a significant decrease
of EPC numbers, as determined by flow cytometry and
in vitro culture [72]. However, only CFU-ECs were eval-
uated in this study, and as previously discussed, this spe-
cial subpopulation of EPCs is probably monocytic in
origin, with limited capacity to be incorporated into the
microvasculature, but may still promote angiogenesis by
the release of proangiogenic factors [73]. These observa-
tions were further substantiated by Deschaseaux et al
[74], who demonstrated that statin-induced depression
of EPCs was only attributed to CFU-ECs, whereas the
ECFC populations, were preserved or even enhanced in
the circulation by long-term statin treatment.
In summary, the effects of statins on EPCs are com-
plex. They help to mobilize early EPCs, which is espe-
cially important in acute ischaemic conditions such as
AMI, but strong long-term positive effects of statins
may be partly explained by augmentation of ECFC,
which are believed to be ‘true EPCs’ responsible for
vasculogenesis.
ACE inhibitors and Angiotensin II receptor blockers
Angiotensin II subtype 1-receptor blockade increases the
number of EPCs, an effect which seems to be common
to all angiotensin II receptor antagonists [75]. VEGF
appears to be involved in angiotensin receptor blocker-
mediated EPC stimulation [32].
Min et al showed that treatment with ramipril 5 mg
daily for 4 weeks in patients with CAD was associated
with an approximately 1.5-fold increase in the number
of circulating EPCs within 1 week of initiating treatment
[33]. This trend persisted with increased levels to
approximately 2.5-fold throughout the 4-week study
period. In addition, increases in the functional activity of
EPCs - as assessed by their proliferation, migration,
adhesion and in vitro vasculogenesis capacity - was also
seen. Broadly similar effects were also seen with enala-
pril, as shown in a study by Wang et al, whereby
patients on enalapril displayed a significant increase in
circulating EPCs in response to ischemic stress [76].
Enalapril also caused a 6-fold increase in the contribu-
tion of bone marrow-derived EPCs to the ischemia-
induced neovascularization.
Other therapeutic approaches
Administration of the PPAR-gamma agonists has been
associated with elevation of EPC numbers and improve-
ment of their function [77]. For example, rosiglitazone
was shown to attenuate the negative effects of C-reactive
protein on EPCs and enhance NO-production of EPCs
[78]. Other available data indicate that positive effects of
PPAR-gamma agonists on EPCs may be one of mechan-
isms on the cardiovascular system [78,79]. In addition to
the effects of PPAR-gamma agonists on EPCs, another
P P A Rs u b t y p e- t h eP P A Ra gonists- has recently
attracted attention. For example, Han et al showed
PPAR agonists modulate CFU-EC promoting vasculo-
genesis [80]. There are also provasculogenic effects of
PPAR agonists on ECFCs [81].
Oestrogens augment production and survival of EPCs,
thereby increasing the circulating levels of these cells
[82]. Moreover, oestrogens not only increase EPC count,
but also their ability to effectively home to the sites of
vascular lesions [82]. Oestradiol may enhances EPC
mobilization though NO-mediated pathways [83].
Implantation of CD34 antibody coated stents
Treatment options for CAD include the mechanical
dilatation of one or more areas of narrowing within the
coronary artery using percutaneous coronary interven-
tion (PCI). The original ‘balloon-only’ technique was
improved by the use of bare-metal stents (BMS). How-
ever, BMSs are still prone to restenosis in up to 30% of
patients [84]. To reduce stent restenosis, the use of
DESs which can elute antimitotic medications has
become widespread. However, DES use has been asso-
ciated with late stent thrombosis [85,86]. Indeed, the
risk of stent thrombosis with DES is greater than that
seen with BMS due to impaired endothelial healing and
delayed endothelialisation [87].
In contrast, endothelialisation with a third type of
stent, the CD34 antibody coated stents based on EPC
capture technology, usually occurs within 7 days in ani-
mal studies [88]. Rapid endothelialisation and restora-
tion of endothelial function may have several
Table 3 Effect of drug treatments on EPC number and function
Medication Effect on EPC number and function Reference
Atorvastatin Increased EPC number and migration [20]
Simvastatin, Mevastatin, Atorvastatin Increased proliferation [114]
Simvastatin Increased adhesion [69]
Atorvastatin, ezetimibe Increased EPC number [115]
Valsartan Reduced senescence [32]
Ramipril Increased EPC number, proliferation, migration, adhesion, in vitro vasculogenesis capacity [33]
Rosiglitazone Increase in EPC culture and migration [116]
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stent thrombosis rate. In addition, early cessation of
dual antiplatelet therapy may be possible, reducing the
inherent risk of this.
Effectiveness of CD34 covered stents has been tested
in a series of studies performed under the HEALING
(Healthy Endothelial Accelerated Lining Inhibits Neoin-
timal Growth) program. The first of these studies was
the Healthy Endothelial Accelerated Lining Inhibits
Neointimal Growth-First In Man (HEALING-FIM) Reg-
istry which demonstrated feasibility and safety of EPC
capture by CD34 covered stents in stable CAD [89].
Subsequently, the HEALING II and the HEALING III
studies, and ultimately the real-world e-Healing multi-
center registry of the Genous™ pro-healing EPC captur-
ing stent (OrbusNeich, Netherlands) have been
performed.
The e-Healing registry established that the rates of
cardiac death, MI and target lesion revascularization
with the CD34 covered stents were low and comparable
to the early Taxus registry studies [90]. These stents
were also tested for use in primary PCI in patients with
AMI. Implantation of these stents was associated with
relatively low rate of major adverse cardiac events: 1.6%
in-hospital, 4.2% at 30 days, 5.8% at 6 months, and 9.2%
at 1 year; there was 1 patient each with acute and suba-
cute stent thrombosis but no incidence of late stent
thrombosis [91]. When used in ‘high risk’ patients (33%
with diabetes, 73% with ACS, 8% with left ventricular
dysfunction, 9% with multivessel intervention, 56% type
B2/C lesions) 14 month follow-up revealed an event rate
of 13% for noncardiac death and AMI, 13% for repeated
percutaneous revascularization and 4% for de novo
lesions [92]. No bypass surgery was preformed. The
study showed that the CD34-covered stents were safe
and effective, with satisfactory immediate results and
mid-term outcome, without evidence of stent
thrombosis
In a recent report from the ongoing multi-centre, ran-
domized the Tri-stent adjudication (TRIAS) study
CD34-covered stents were as effective as paclitaxel-elut-
ing stents for the prevention of re-stenosis during 12-
month follow-up; however, 4 cases of out-of-hospital
thrombotic events were reported for paclitaxel-covered
stents, whilst no such events were reported in patients
with implanted CD34-covered stents [93].
Transplantation of EPCs
The available data that demonstrate angiogenic proper-
ties of EPCs and favorable outcomes of animal studies
have encouraged clinical trials in patients with ischemic
heart disease, particularly in the AMI setting [94]. How-
ever, results of human studies have proved to be contro-
versial with some trials reporting significant
improvement in cardiac vascularisation and performance
while others failing to show any benefits. Results of ran-
domized clinical studies are on cardiac transplantation
of cells with endothelial progenitor potential are sum-
marized in table 4.
The majority of completed randomized trials have
demonstrated some benefits of stem cells treatment, and
studies uniformly report the safety of this approach with
no specific adverse events observed (including proar-
rhythmia, oncology or excessive inflammatory burden)
[95,96]. High rate of in-stent restenosis in the MAGIC
study where cell therapy was combined with G-CSF
administration has been discussed above [59]. In the
BOOST trial, intracoronary implantation of bone marrow
cells did not provide long-term benefit on left ventricular
systolic function after AMI compared to a randomized
control group; however, stem cell therapy was associated
with acceleration of left ventricular recovery [97].
In the study by Janssens et al [98], transfer of bone
marrow stem cells to the coronary artery in 67 patients
with AMI did not contributed to improvement of the
global left ventricular function, but did favorably
affected infarct remodelling at 4 months follow-up, with
a reduction in infarct size. In the double-blind, placebo-
controlled multicentre REPAIR-AMI trial, 204 patients
with MI were randomized to bone marrow-derived cells
or placebo [99]. At 12 months, the pre-specified cumu-
lative endpoint of death, myocardial infarction, or neces-
sity for revascularization was significantly reduced in the
stem cell-therapy group compared with placebo; of note,
stem cells therapy was an independent predictor of a
favorable clinical outcome in this study [99].
Alternative to intracoronary infusion routs of stem cell
delivery such as intramyocardial implantation (either
during cardiac surgery on NOGA system) have also
been tested [100,101]. In the only randomised with per-
cutaneous transendocardial injections of CD34+ cells to
patient with severe intractable angina, this method was
found to be feasible and safe and is being extended into
a larger ongoing phase IIb study [102].
Given the controversy of trial results, important issues
have arisen about the factors affecting the efficacy of
such therapy. In addition to route of administration, the
time of stem cell delivery (ie. after AMI), origin and
number of cells used may be critical. In fact, the major-
ity of studies have used unselected mononuclear cells
with unknown but evidently very low proportion of
endothelial progenitors but with progenitors of other
origins (eg. mesenchimal stem cells), this could be
potentially favorable for cardiac recovery. Indeed, when
either bone marrow or circulating mononuclear cells
were delivered to infarct-related coronary arteries, treat-
ment with bone morrow cells resulted in a better
improvement of left ventricular contractility, when
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with selected CD34+, CD133+ cells or cultured periph-
eral blood EPCs have been successfully performed but
large controlled studies are required to evaluate their
clinical utility [102,104,105].
Although different factors may impair EPCs-mediated
vascular repair (for example, abnormality in their mobilisa-
tion from bone marrow and homing to the damaged vas-
cular tissues, and exhaustion of their bone marrow niche),
the available data strongly indicate functional characteris-
tics of circulating endothelial progenitors are relevant.
Accordingly, appropriate genetic modification of EPCs
before their implantation may be a way to improve their
angiogenic potential. The feasibility of this approach has
been demonstrated by genetic inhibition of glycogen
synthase kinase-3b signaling in human EPCs that was
associated with significant enhancement of their angio-
genic properties in an animal model of ischaemia [106].
Additionally, the angiogenic potential of EPCs can be
improved by non-genetic ex-vivo stimulus (for example,
by exposure to hypoxia). However, the clinical relevance
of these approaches needs further investigation [107].
Understanding of EPCs - where we are now?
D e s p i t em o r et h a tad e c a d eo fvery intensive research
and many studies devoted to the problem of
understanding EPC biology, their potential clinical role
is still largely limited by lack of a consensus on the phe-
notypic and functional definition of endothelial precur-
sors [108]. At present, a single term ‘EPC’ refers to a
very diverse group of cells of different lineages which
appear to have some angiogenic potential, but not
necessarily the ability to differentiate into functional
endothelial cells, as expected from their name. Accord-
ingly, a booming number of new publications on ‘EPCs’
may have limited scientific impact without a clear
understanding what type of cell is actually being
analysed.
C u r r e n t l yo n l ys o - c a l l e d‘outgrowth endothelial cells’
(or ‘late’ EPCs) are known to uniformly give origin to
functional endotheliocytes. Indeed, CD34 or CD133 and
alone or in different combinations (often with KDR) are
the most popular markers used to define ‘circulating
EPCs’. This popularity stems from initial reports show-
ing that CD34+/KDR+ cells could form endothelium-
like cells in vitro [4,109]. Although many studies have
employed CD34+/CD133+/KDR+ cells as their defini-
tion of ‘true EPCs’ their ability to generate endothelial
cells has never been reliably proved. Furthermore, these
cell populations probably represents a subset of CD45+
haematopoietic progenitors but do not form endothelial
cells in vitro [110]. Inclusion of any additional markers
Table 4 Randomized clinical studies on transplantation of cells which include endothelial progenitors
Study/year Disorder N Delivery
route
Cells delivered Follow-up
(months)
Effectiveness
Strauer et al. (2002) [117] AMI 20 Intracoronary BM-MNCs 4 Effective
Kang et al. MAGIC (2004) [92] AMI
Old MI
27 Intracoronary PB-MNCs and G-
CSF
6 Effective, but high rate of in-stent
re-stenosis
Schachinger et al. TOPCARE-AMI
(2004) [118]
AMI 59 Intracoronary PB-MNCs or BM-
MNCs
12 Effective
Ruan et al. (2005) [119] Acute MI 20 Intracoronary BM-MNCs 6 Effective
Strauer et al. IACT (2005) [120] Chronic
CAD
36 Intracoronary BM-MNCs 3 Effective
Bartunek et al. (2005) [111] Recent MI 35 Intracoronary CD133+ 4 Effective
Erbs et al. (2005) [112] Chronic
CAD
26 Intracoronary Cultured PB-EPCs 3 Effective
Assmus et al. (2006) [111] Chronic
CAD
53 Intracoronary BM-MNCs 3 Effective
Meyer et al. BOOST (2006) [104] Acute MI 60 Intracoronary BM-MNCs 18 Effective at 6 month, ineffective at
18 month
Hendrikx et al. (2006) [121] Heart
failure
20 Intramyocardial BM-MNCs 4 Ineffective
Janssens et al. (2006) [105] MI 67 Intracoronary BM-MNCs 4 Ineffective
Kang et al. MAGIC Cell-3-DES (2006)
[60]
Acute MI
Old MI
82 Intracoronary PB-MNCs and G-
CSF
6 Effective
Schachinger et al. REPAIR-AMI (2006)
[106,122]
AMI 201 Intracoronary BM-MNCs 12 Effective
Ge et al. TCT-STAMI (2006) [95] MI 20 Intracoronary BM-MNCs 6 Effective
Meluzin et al. (2007) [122] Acute MI 60 Intracoronary BM-MNCs 12 Effective
AMI - acute myocardial infarction, BM - bone marrow, CAD - coronary artery disease, G-CSF - granulocyte-colony stimulating factor, MI - myocardial infarction,
MNC - mononuclear cell, PB - peripheral blood.
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approach towards EPC analysis even further and should
only be based on robust data confirming the functional
identity of the cells analysed.
The problem with the identification of functional
EPCs is also present with approached based on cell cul-
ture. For example, markers previously used to prove
endothelial identity of putative progenitors, such as
CD31, lectin binding or LDL accumulation are now
k n o w nt ob en o n - s p e c i f i cf o rt h ee n d o t h e l i a ll i n e a g e ,
but also characteristic for cells of haematopoietic origin]
[111,112]. In fact, the majority of so called ‘early’ EPCs
represent populations of monocytes and lymphocytes
which co-express ‘endothelial’ markers and possess
some degree of angiogenic capacity [36]. This reempha-
sises that the initiation of any new clinically-relevant
study on EPCs should only be based on clear under-
standing of type of cells being analysed.
Conclusion
Since the discovery of EPCs, there has been a rapid pro-
liferation of research data on the relation of EPC to car-
diovascular risk, pathology and treatment. So far, EPCs
have been implicated in the whole cardiovascular disease
process, and many conventional therapies have been
shown to alter EPC number and function. More
recently, attempts to utilise the clinical potential of
EPCs such as in the form of CD34-antibody coated
stents, has been attempted. Further challenges will be to
develop simple techniques to measure EPCs numbers
and function accurately and quickly, as these cells may
help determine cardiac risk and outcomes for patients
with heart disease.
Abbreviations
ACS: acute coronary syndrome; AMI: acute myocardial infarction; BMS: bare-
metal stents; CAD: coronary artery disease; CEC: circulating endothelial cells;
CFU-EC: colony forming unit-endothelial cell; ECFC: endothelial colony
forming cells; eNOS: endothelial nitric oxide synthase; EPC: endothelial
progenitor cell; G-CSF: granulocyte-colony stimulating factor; HUVEC: human
umbilical vein endothelial cells; KDR: kinase insert domain receptor; NO:
nitric oxide; PCI: percutaneous coronary intervention; TERT: telomerase
reverse transcriptase; TRF: telomere repeat-binding factors; VEGF: vascular
endothelial growth factor
Author details
1Haemostasis, Thrombosis and Vascular Biology Unit, University of
Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
UK.
2Department of Cardiology, City Hospital, Birmingham, UK.
Authors’ contributions
AS - selected publications for the review, drafted manuscript; ES -
participated in the design of the review, drafted manuscript; GYHL -
designed manuscripts, edited manuscript; CV - edited manuscript. All
authors read and approved the final manuscript.
Competing interests
AS is funded by a research grant from Orbus Neisch (Orbus Neisch,
Netherlands). ES is funded by a research grant of the Heart Failure
Association of European Society of Cardiology. CV is UK national
coordinating investigator for the TRIAS programme. GL and CV are both
investigators in the TRIAS trials.
Received: 8 December 2009
Accepted: 22 February 2010 Published: 22 February 2010
References
1. Dong C, Goldschmidt-Clermont PJ: Endothelial progenitor cells: a
promising therapeutic alternative for cardiovascular disease. J Interv
Cardiol 2007, 20:93-9.
2. Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med 1999,
340:115-125.
3. Stump MM, Jordan GLJ, DeBakey ME, Halpert B: Endothelium grown from
circulating blood on isolated intravascular Dacron hub. Am J Pathol 1963,
43:361-367.
4. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M,
Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells
responsible for postnatal vasculogenesis in physiological and
pathological neovascularization. Circ Res 1999, 85:221-228.
5. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF,
Sauvage LR, Hammond WP, Wu MH: Enhanced endothelialization and
microvessel formation in polyester grafts seeded with CD34 (+) bone
marrow cells. Blood 2000, 95:581-585.
6. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M,
Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK,
Fiedler W: In vitro differentiation of endothelial cells from AC133-positive
progenitor cells. Blood 2000, 95:3106-3112.
7. Hu Y, Davison F, Zang Z, Xu Q: Endothelial replacement and angiogenesis
in arteriosclerotic lesions of allografts are contributed by circulating
progenitor cells. Circulation 2003, 108:3122-3127.
8. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA,
Finkel T: Circulating endothelial progenitor cells, vascular function, and
cardiovascular risk. N Engl J Med 2003, 348:593-600.
9. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM,
Dimmeler S: Number and migratory capacity of circulating Endothelial
Progenitor Cells inversely correlate with risk factors for coronary artery
disease. Circ Res 2001, 89:1-7.
10. Jie KE, Goossens MH, van Oostrom O, Lilien MR, Verhaar MC: Circulating
endothelial progenitor cell levels are higher during childhood than in
adult life. Atherosclerosis 2009, 202:345-347.
11. Schaffer RG, Greene S, Arshi A, Supple G, Bantly A, Moore JS, Parmacek MS,
Mohler ER: Effect of acute exercise on endothelial progenitor cells in
patients with peripheral arterial disease. Vasc Med 2006, 11:219-226.
12. Hoetzer GL, Van Guilder Gary GP, Irmiger HM, Keith RS: Aging, exercise,
and endothelial progenitor cell clonogenic and migratory capacity in
men. J Appl Physiol 2007, 102:847-852.
13. Pelliccia F, Pasceri V, Meoni G, Pristipino C, Cianfrocca C, Li X, La Rocca S,
Rosano G, Mercuro G, Richichi G: Numbers of endothelial progenitor cells
in peripheral blood are similar in younger and older patients with
coronary artery disease. Int J Cardiol 2009, 133:277-279.
14. Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin S, Bastidas N, Aarabi S,
Chan DA, Freedman ML, Giaccia AJ, Gurtner GC: Age decreases
endothelial progenitor cell recruitment through decreases in hypoxia-
inducible factor 1 stabilization during ischemia. Circulation 2007,
116:2818-2829.
15. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E,
Böhm M, Nickenig G: Physical Training Increases Endothelial Progenitor
Cells, Inhibits Neointima Formation, and Enhances Angiogenesis.
Circulation 2004, 109:220-226.
16. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D,
Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA: Aging,
progenitor cell exhaustion, and atherosclerosis. Circulation 2003,
108:457-463.
17. Maisel AS, Knowlton KU, Fowler P, Rearden A, Ziegler MG, Motulsky HJ,
Insel PA, Michel MC: Adrenergic control of circulating lymphocyte
subpopulations. Effects of congestive heart failure, dynamic exercise,
and terbutaline treatment. J Clin Invest 1990, 85:462-467.
18. Rehman J, Li J, Parvathaneni L, Karlsson G, Panchal VR, Temm CJ,
Mahenthiran J, March KL: Exercise acutely increases circulating
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6
Page 9 of 13endothelial progenitor cells and monocyte-/macrophage-derived
angiogenic cells. J Am Coll Cardiol 2004, 43:2314-2318.
19. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG:
Regulation of the vascular extracellular superoxide dismutase by nitric
oxide and exercise training. J Clin Invest 2000, 105:1631-1639.
20. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S:
Increase in circulating endothelial progenitor cells by statin therapy in
patients with stable coronary artery disease. Circulation 2001,
103:2885-2890.
21. Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA, Finkel T:
Endothelial progenitor cells as putative targets for angiostatin. Cancer
Res 1999, 59:5875-5877.
22. Li D, Yang B, Mehta JL: Ox-LDL induces apoptosis in human coronary
artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol
1998, 275:568-576.
23. Chen JZ, Zhang FR, Tao OM, Wang XX, Zhu JH, Zhu JH: Number and
activity of endothelial progenitor cells from peripheral blood in patients
with hypercholesterolaemia. Clinical Science 2004, 107:273-280.
24. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, Dimmeler S:
Oxidized LDL inhibits VEGF-induced endothelial cell migration by an
inhibitory effect on the Akt/eNOS pathway. Circulation 2001,
103:2102-2107.
25. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, Sessa WC:
Vascular endothelial growth factor-stimulated actin reorganization and
migration of endothelial cells is regulated via the serine/threonine
kinase Akt. Circ Res 2000, 86:892-896.
26. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR,
Levine JP, Gurtner GC: Human endothelial progenitor cells from type 2
diabetics exhibit impaired proliferation, adhesion, and incorporation into
vascular structures. Circulation 2002, 106:2781-2786.
27. Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS,
Wecker A, Luedemann C, Eaton E, Silver M, Thorne T, Losordo DW:
Endothelial progenitor thrombospondin-1 mediates diabetes-induced
delay in reendothelialization following arterial injury. Circ Res 2006,
98:697-704.
28. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL,
Chen JW: High Glucose Impairs Early and Late Endothelial Progenitor
Cells by Modifying Nitric Oxide-Related but Not Oxidative Stress-
Mediated Mechanisms. Diabetes 2007, 56:1559-1568.
29. Imanishi T, Hano T, Nishio I: Angiotensin II potentiates vascular
endothelial growth factor-induced proliferation and network formation
of endothelial progenitor cells. Hypertens Res 2004, 27:101-108.
30. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY: Improvement in endothelial
progenitor cells from peripheral blood by ramipril therapy in patients
with stable coronary artery disease. Cardiovasc Drugs Ther 2004, 18:203-9.
31. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M,
Nickenig G: Circulating endothelial progenitor cells and cardiovascular
outcomes. N Engl J Med 2005, 353:999-1007.
32. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y,
Murohara T: Smoking cessation rapidly increases circulating progenitor
cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol
2004, 24:1442-7.
33. Wang XX, Zhu JH, Chen JZ: Effects of Nicotine on the Number and
Activity of Circulating Endothelial Progenitor Cells. J Clin Pharmacol 2004,
44:881-889.
34. Shantsila E, Watson T, Lip GY: Statins and inflammation: reciprocal
effectors to endothelial progenitors?. Thromb Res 2008, 123:1-4.
35. Shantsila E, Watson T, Lip GY: Antioxidant protection: yet another
function of endothelial progenitor cells?. J Hum Hypertens 2007, 21:343-6.
36. Shantsila E, Watson T, Lip GY: Endothelial progenitor cells in
cardiovascular disorders. J Am Coll Cardiol 2007, 49:741-52.
37. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U,
Dimmeler S, Zeiher AM: Reduced number of circulating endothelial
progenitor cells predicts future cardiovascular events: Proof of concept
for endogenous vascular repair. Circulation 2005, 111:2981-2987.
38. Boos CJ, Blann AD, Lip GYH: Circulating endothelial cells in cardiovascular
disease. J Am Coll Cardiol 2006, 48:1538-47.
39. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY: Endothelial
dysfunction and damage in congestive heart failure: relation of flow-
mediated dilation to circulating endothelial cells, plasma indexes of
endothelial damage, and brain natriuretic peptide. Circulation 2004,
110:1794-1798.
40. Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY: Assessment of
endothelial damage in atherosclerotic vascular disease by quantification
of circulating endothelial cells. Eur Heart J 2004, 25:371-376.
41. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Poole-
Wilson PA, Ertl G, Bauersachs J: Suppression of Endothelial Progenitor
Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide
Synthase Inhibitor Asymmetric Dimethylarginine. J Am Coll Cardiol 2005,
46:1693-1701.
42. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, Goldschmidt-
Clermont PJ, Dong C, Taylor DA, Peterson ED: Circulating endothelial
progenitor cells predict coronary artery disease severity. Am Heart J 2006,
152:190-5.
43. Güven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC: The number of
endothelial progenitor cell colonies in the blood is increased in patients
with angiographically significant coronary artery disease. J Am Coll
Cardiol 2006, 48:1579-87.
44. Werner N, Wassmann S, Ahlers P, Schiegl T, Kosiol S, Link A, Walenta K,
Nickenig G: Endothelial progenitor cells correlate with endothelial
function in patients with coronary artery disease. Basic Res Cardiol 2007,
102:565-71.
45. Wojakowski W, Tendera M, Michałowska A, Majka M, Kucia M,
Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ: Mobilization of CD34/
CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells
expressing early cardiac, muscle, and endothelial markers into
peripheral blood in patients with acute myocardial infarction. Circulation
2004, 110:3213-20.
46. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De
Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R:
Increased circulating hematopoietic and endothelial progenitor cells in
the early phase of acute myocardial infarction. Blood 2005, 105:199-206.
47. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S,
Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM,
Leone G, Crea F: Mobilization of bone marrow-derived stem cells after
myocardial infarction and left ventricular function. Eur Heart J 2005,
26:1196-1204.
48. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K,
Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor
cells in patients with acute myocardial infarction. Circulation 2001,
103:2776-9.
49. Numaguchi Y, Sone T, Okumura K, Ishii M, Morita Y, Kubota R, Yokouchi K,
Imai H, Harada M, Osanai H, Kondo T, Murohara T: The impact of the
capability of circulating progenitor cell to differentiate on myocardial
salvage in patients with primary acute myocardial infarction. Circulation
2006, 114:I114-9.
50. Gaspardone A, Menghini F, Mazzuca V, Skossyreva O, Barbato G, de
Fabritiis P: Progenitor cell mobilisation in patients with acute and
chronic coronary artery disease. Heart 2006, 92:253-4.
51. Wojakowski W, Kucia M, Kaźmierski M, Ratajczak MZ: Circulating progenitor
cells in stable coronary heart disease and acute coronary syndromes:
relevant reparatory mechanism?. Heart 2008, 94:27-33.
52. Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O,
Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G,
Ferrari R: CD34+ and endothelial progenitor cells in patients with various
degrees of congestive heart failure. Circulation 2004, 110:1209-12.
53. Nonaka-Sarukawa M, Yamamoto K, Aoki H, Nishimura Y, Tomizawa H,
Ichida M, Eizawa T, Muroi K, Ikeda U, Shimada K: Circulating endothelial
progenitor cells in congestive heart failure. Int J Cardiol 2007, 119:344-8.
54. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A,
Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D,
Mueller M, Fuchs M, Hornig B, Haller H, Drexler H: Statin-induced
improvement of endothelial progenitor cell mobilization, myocardial
neovascularization, left ventricular function, and survival after
experimental myocardial infarction requires endothelial nitric oxide
synthase. Circulation 2004, 110:1933-9.
55. Michowitz Y, Goldstein E, Wexler D, Sheps D, Keren G, George J: Circulating
endothelial progenitor cells and clinical outcome in patients with
congestive heart failure. Heart 2007, 93:1046-50.
56. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P:
Role of the endothelium in modulating neointimal formation:
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6
Page 10 of 13vasculoprotective approaches to attenuate restenosis after percutaneous
coronary interventions. J Am Coll Cardiol 2004, 44:733-9.
57. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G:
Intravenous transfusion of endothelial progenitor cells reduces
neointima formation after vascular injury. Circ Res 2003, 93:17-24.
58. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B,
Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P,
Hoffmann R, Weber C: A novel drug-eluting stent coated with an
integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal
hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol
2006, 47:1786-95.
59. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D,
Sohn DW, Han KS, Oh BH, Lee MM, Park YB: Effects of intracoronary
infusion of peripheral blood stem-cells mobilised with granulocyte-
colony stimulating factor on left ventricular systolic function and
restenosis after coronary stenting in myocardial infarction: the MAGIC
cell randomised clinical trial. Lancet 2004, 363:751-6.
60. Kang HJ, Lee HY, Na SH, Chang SA, Park KW, Kim HK, Kim SY, Chang HJ,
Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB,
Kim HS: Differential effect of intracoronary infusion of mobilized
peripheral blood stem cells by granulocyte colony-stimulating factor on
left ventricular function and remodeling in patients with acute
myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-
DES randomized, controlled trial. Circulation 2006, 114:I145-51.
61. Lim SY, Kim YS, Ahn Y, Jeong MH, Rok LS, Kim JH, Kim KH, Park HW, Kim W,
Cho JG, Park JC, Kang PM, Schwartz RS, Kang JC: The effects of
granulocyte-colony stimulating factor in bare stent and sirolimus-eluting
stent in pigs following myocardial infarction. Int J Cardiol 2007,
118:304-11.
62. Schober A, Hoffmann R, Oprée N, Knarren S, Iofina E, Hutschenreuter G,
Hanrath P, Weber C: Peripheral CD34+ cells and the risk of in-stent
restenosis in patients with coronary heart disease. Am J Cardiol 2005,
96:1116-22.
63. Cho HJ, Kim TY, Cho HJ, Park KW, Zhang SY, Kim JH, Kim SH, Hahn JY,
Kang HJ, Park YB, Kim HS: The effect of stem cell mobilization by
granulocyte-colony stimulating factor on neointimal hyperplasia and
endothelial healing after vascular injury with bare-metal versus
paclitaxel-eluting stents. J Am Coll Cardiol 2006, 48:366-74.
64. Tuleta I, Skowasch D, Peuster M, Nickenig G, Bauriedel G: Cells of primarily
extravascular origin in neointima formation following stent implantation:
coordinated expression of endothelial progenitor, dendritic and neural
crest-derived cells. Cardiology 2008, 110:199-205.
65. Inoue T, Masataka S, Yutaka H, Sohma R, Fukuda D, Uchida T, Shimizu M,
Komoda H, Node K: Mobilization of CD34 positive bone marrow-derived
cells after coronary stent implantation: impact on restenosis. Circulation
2007, 115:553-561.
66. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK,
Fiedler W: Rapamycin inhibits proliferation and differentiation of human
endothelial progenitor cells in vitro. Exp Cell Res 2004, 300:65-71.
67. Gautam K, Lee MS: Stent thrombosis with drug-eluting stents: a re-
examination of the evidence. Catheter Cardiovasc Interv 2007, 69:782-9.
68. Matsuo Y, Imanishi T, Hayashi Y, Tomobuchi Y, Kubo T, Hano T, Akasaka T:
The Effect of senescence of endothelial progenitor cells on in-stent
restenosis in patients undergoing coronary stenting. Intern Med 2006,
45:581-7.
69. Smadja DM, Godier A, Susen S, Packard RR, Fabiani JN, Aiach M, Gaussem P:
Endothelial progenitor cells are selectively mobilised immediately after
coronary artery bypass grafting or valve surgery. Thromb Haemost 2009,
101:983-5.
70. Choi YH, Neef K, Reher M, Liakopoulos OJ, Zeriouh M, Wittwer T, Stamm C,
Madershahian N, Teschendorf P, Wahlers T: The influence of pre-operative
risk on the number of circulating endothelial progenitor cells during
cardiopulmonary bypass. Cytotherapy 2010, 12:79-87.
71. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T,
Nishimura H, Losordo DW, Asahara T, Isner JM, Walter DH, Rittig K,
Bahlmann FH: Statin Therapy Accelerates Reendothelialization. Circulation
2002, 105:3017-24.
72. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P,
Weber C: Reduced numbers of circulating endothelial progenitor cells in
patients with coronary artery disease associated with long-term statin
treatment. Atherosclerosis 2007, 192:413-20.
73. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY: Endothelial
dysfunction and damage in congestive heart failure: relation of flow-
mediated dilation to circulating endothelial cells, plasma indexes of
endothelial damage, and brain natriuretic peptide. Circulation 2004,
110:1794-1798.
74. Deschaseaux F, Selmani Z, Falcoz PE, Mersin N, Meneveau N, Penfornis A,
Kleinclauss C, Chocron S, Etievent JP, Tiberghien P, Kantelip JP, Davani S:
Two types of circulating endothelial progenitor cells in patients
receiving long term therapy by HMG-CoA reductase inhibitors. Eur J
Pharmacol 2007, 562:111-8.
75. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D:
Stimulation of Endothelial Progenitor Cells A New Putative Therapeutic
Effect of Angiotensin II Receptor Antagonists. Hypertension 2005, 45:526.
76. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, Yang NI, Wang SY, Wu MY,
Hsu CM, Cheng CW, Cherng WJ: Enalapril increases ischemia-induced
endothelial progenitor cell mobilization through manipulation of the
CD26 system. J Mol Cell Cardiol 2006, 41:34-43.
77. Werner C, Kamani CH, Gensch C, Böhm M, Laufs U: The peroxisome
proliferator-activated receptor-gamma agonist pioglitazone increases
number and function of endothelial progenitor cells in patients with
coronary artery disease and normal glucose tolerance. Diabetes 2007,
56:2609-15.
78. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI:
Effect of rosiglitazone treatment on nontraditional markers of
cardiovascular disease in patients with type 2 diabetes mellitus.
Circulation 2002, 106:679-684.
79. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH,
Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-
Reactive Protein Attenuates Endothelial Progenitor Cell Survival,
Differentiation, and Function Further Evidence of a Mechanistic Link
Between C-Reactive Protein and Cardiovascular Disease. Circulation 2004,
109:2058-67.
80. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM,
Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS: Peroxisome
proliferator-activated receptor-delta agonist enhances vasculogenesis by
regulating endothelial progenitor cells through genomic and
nongenomic activations of the phosphatidylinositol 3-kinase/Akt
pathway. Circulation 2008, 118:1021-1033.
81. He T, Lu T, d’Uscio LV, Lam CF, Lee HC, Katusic ZS: Angiogenic function of
prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res
2008, 103:80-88.
82. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K,
Ghaeni L, Milosevic M, Böhm M, Nickenig G: Estrogen Increases Bone
Marrow-Derived Endothelial Progenitor Cell Production and Diminishes
Neointima Formation. Circulation 2003, 107:3059-65.
83. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R,
Isner JM, Asahara T, Losordo DW: Estrogen-mediated, endothelial nitric
oxide synthase-dependent mobilization of bone marrow-derived
endothelial progenitor cells contributes to reendothelialization after
arterial injury. Circulation 2003, 108:3115-21.
84. Bourassa MG, Wilson JW, Detre KM, Kelsey SF, Robertson T, Passamani ER:
Long-term follow-up of coronary angioplasty: the 1977-1981 National
Heart, Lung, and Blood Institute registry. Eur Heart J 1989, 10:36-41.
85. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T,
Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF,
Waksman R, Serruys PW: Late thrombosis in drug-eluting coronary stents
after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
86. Ong AT, McFadden E, Regar E, de Jaegere PP, van Domburg RT,
Serruys PW: Late angiographic stent thrombosis (LAST) events with drug-
eluting stents. J Am Coll Cardiol 2005, 45:2088-2092.
87. Losordo DW, Isner JM, Diaz-Sandoval LJ: Endothelial Recovery The Next
Target in Restenosis Prevention. Circulation 2003, 107:2635-37.
88. Kutryk MJ, Kuliszewski MA: In vivo endothelial progenitor cell seeding for
the accelerated endothelialization of endovascular devices. Am J Cardiol
2003, 92:94-98.
89. Aoki J, Serruys PW, van Beusekom H: Endothelial progenitor cell capture
by stents coated with antibody against CD34: the HEALING-FIM (Healthy
Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man)
Registry. J Am Coll Cardiol 2005, 45:1574-9.
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6
Page 11 of 1390. Zhou Z, Shi S, Song M, Huang H, Chen K, Mi J, Li L, Chen G, Hou C,
Huang G, Zhu C: Development of transgenic endothelial progenitor cell-
seeded stents. J Biomed Mater Res A 2009, 91:623-8.
91. Co M, Tay E, Lee CH, Poh KK, Low A, Lim J, Lim IH, Lim YT, Tan HC: Use of
endothelial progenitor cell capture stent (Genous Bio-Engineered R
Stent) during primary percutaneous coronary intervention in acute
myocardial infarction: intermediate- to long-term clinical follow-up. Am
Heart J 2008, 155:128-32.
92. Miglionico M, Patti G, D’Ambrosio A, Di Sciascio G: Percutaneous coronary
intervention utilizing a new endothelial progenitor cells antibody-coated
stent: a prospective single-center registry in high-risk patients. Catheter
Cardiovasc Interv 2008, 71:600-4.
93. Klomp M, Beijk MA, Verouden NJ, Tijssen JG, de Winter RJ, TRIAS
Investigators: Design and rationale of the TRI-stent adjudication study
(TRIAS) program. Am Heart J 2009, 158:527-532.
94. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C,
Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M,
Losordo DW, Isner JM, Asahara T: Intramyocardial transplantation of
autologous endothelial progenitor cells for therapeutic
neovascularization of myocardial ischemia. Circulation 2003, 107:461-8.
95. Ge J, Li Y, Qian J, Shi J, Wang Q, Niu Y, Fan B, Liu X, Zhang S, Sun A, Zou Y:
Efficacy of emergent transcatheter transplantation of stem cells for
treatment of acute myocardial infarction (TCT-STAMI). Heart 2006,
92:1764-7.
96. Meluzín J, Janousek S, Mayer J, Groch L, Hornácek I, Hlinomaz O, Kala P,
Panovský R, Prásek J, Kamínek M, Stanícek J, Klabusay M, Korístek Z,
Navrátil M, Dusek L, Vinklárková J: Three-, 6-, and 12-month results of
autologous transplantation of mononuclear bone marrow cells in
patients with acute myocardial infarction. Int J Cardiol 2008, 128:185-92.
97. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H,
Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H: Intracoronary
bone marrow cell transfer after myocardial infarction: eighteen months’
follow-up data from the randomized, controlled BOOST (BOne marrOw
transfer to enhance ST-elevation infarct regeneration) trial. Circulation
2006, 113:1287-94.
98. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W,
Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F,
Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J,
Belmans A, Mortelmans L, Boogaerts M, Werf Van de F: Autologous bone
marrow-derived stem-cell transfer in patients with ST-segment elevation
myocardial infarction: double-blind, randomised controlled trial. Lancet
2006, 367:113-21.
99. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R,
Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T,
Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T,
Dimmeler S, Zeiher AM, REPAIR-AMI Investigators: Improved clinical
outcome after intracoronary administration of bone-marrow-derived
progenitor cells in acute myocardial infarction: final 1-year results of the
REPAIR-AMI trial. Eur Heart J 2006, 27:2775-83.
100. Mocini D, Staibano M, Mele L, Giannantoni P, Menichella G, Colivicchi F,
Sordini P, Salera P, Tubaro M, Santini M: Autologous bone marrow
mononuclear cell transplantation in patients undergoing coronary artery
bypass grafting. Am Heart J 2006, 151:192-7.
101. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP: Angiogenesis in
ischaemic myocardium by intramyocardial autologous bone marrow
mononuclear cell implantation. Lancet 2003, 361:47-9.
102. Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M,
Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L,
Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH,
Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF,
Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD: Intramyocardial
transplantation of autologous CD34+ stem cells for intractable angina: a
phase I/IIa double-blind, randomized controlled trial. Circulation 2007,
115:3165-72.
103. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U,
Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T,
Dimmeler S, Zeiher AM: Transcoronary transplantation of progenitor cells
after myocardial infarction. N Engl J Med 2006, 355:1222-32.
104. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B,
De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W: Intracoronary
injection of CD133-positive enriched bone marrow progenitor cells
promotes cardiac recovery after recent myocardial infarction: feasibility
and safety. Circulation 2005, 112:I178-83.
105. Erbs S, Linke A, Adams V, Lenk K, Thiele H, Diederich KW, Emmrich F,
Kluge R, Kendziorra K, Sabri O, Schuler G, Hambrecht R: Transplantation of
blood-derived progenitor cells after recanalization of chronic coronary
artery occlusion: first randomized and placebo-controlled study. Circ Res
2005, 97:756-62.
106. Choi JH, Hur J, Yoon CH, Kim JH, Lee CS, Youn SW, Oh IY, Skurk C,
Murohara T, Park YB, Walsh K, Kim HS: Augmentation of therapeutic
angiogenesis using genetically modified human endothelial progenitor
cells with altered glycogen synthase kinase-3beta activity. J Biol Chem
2004, 279:49430-8.
107. Akita T, Murohara T, Ikeda H, Sasaki K, Shimada T, Egami K, Imaizumi T:
Hypoxic preconditioning augments efficacy of human endothelial
progenitor cells for therapeutic neovascularization. Lab Invest 2003,
83:65-73.
108. Hirschi KK, Ingram DA, Yoder MC: Assessing identity, phenotype, and fate
of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008,
28:1584-95.
109. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S,
Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for
circulating bone marrow-derived endothelial cells. Blood 1998, 92:362-7.
110. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR,
Bhavsar JR, Yoder MC, Haneline LS, Ingram DA: Human CD34+AC133
+VEGFR-2+ cells are not endothelial progenitor cells but distinct,
primitive hematopoietic progenitors. Exp Hematol 2007, 35:1109-18.
111. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ,
Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal
analysis and hematopoietic stem/progenitor cell principals. Blood 2007,
109:1801-9.
112. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F,
De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B: Endothelial
outgrowth cells are not derived from CD133+ cells or CD45+
hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007, 27:1572-9.
113. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C: Impaired
progenitor cell activity in age-related endothelial dysfunction. J Am Coll
Cardiol 2005, 45:1441-48.
114. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M,
Rütten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase
inhibitors (statins) increase endothelial progenitor cells via the PI 3-
kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
115. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N,
Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, März W,
Drexler H: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering
effects on endothelial function in humans. Circulation 2005, 111:2356-63.
116. Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S,
Gross P: PPARgamma-agonist rosiglitazone increases number and
migratory activity of cultured endothelial progenitor cells. Atherosclerosis
2005, 183:163-7.
117. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G,
Wernet P: Repair of infarcted myocardium by autologous intracoronary
mononuclear bone marrow cell transplantation in humans. Circulation
2002, 106:1913-8.
118. Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C,
Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM:
Transplantation of progenitor cells and regeneration enhancement in
acute myocardial infarction: final one-year results of the TOPCARE-AMI
Trial. J Am Coll Cardiol 2004, 44:1690-9.
119. Ruan W, Pan CZ, Huang GQ, Li YL, Ge JB, Shu XH: Assessment of left
ventricular segmental function after autologous bone marrow stem cells
transplantation in patients with acute myocardial infarction by tissue
tracking and strain imaging. Chin Med J 2005, 118:1175-81.
120. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV,
Kögler G, Wernet P, Müller HW, Köstering M: Regeneration of human
infarcted heart muscle by intracoronary autologous bone marrow cell
transplantation in chronic coronary artery disease: the IACT Study. JA m
Coll Cardiol 2005, 46:1651-8.
121. Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, Ingels M,
Jacobs A, Geukens R, Dendale P, Vijgen J, Dilling D, Steels P, Mees U,
Rummens JL: Recovery of regional but not global contractile function by
the direct intramyocardial autologous bone marrow transplantation:
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6
Page 12 of 13results from a randomized controlled clinical trial. Circulation 2006, 114:
I101.
122. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R,
Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T,
Assmus B, Tonn T, Dimmeler S, Zeiher AM, REPAIR-AMI Investigators:
Intracoronary bone marrow-derived progenitor cells in acute myocardial
infarction. N Engl J Med 2006, 355:1210-21.
doi:10.1186/2040-2384-2-6
Cite this article as: Siddique et al.: Endothelial progenitor cells: what use
for the cardiologist?. Journal of Angiogenesis Research 2010 2:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Siddique et al. Journal of Angiogenesis Research 2010, 2:6
http://www.jangiogenesis.com/content/2/1/6
Page 13 of 13